Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~To be included in this study, you must meet the following criteria:~* Histologically confirmed non-small cell bronchogenic carcinoma~* Newly diagnosed or recurrent unresectable stage III or stage IV disease~* No mixed tumors with small cell anaplastic elements~* Measurable disease~* Must not have received any prior antineoplastic chemotherapy for lung cancer~* Age \> 18 years~* Able to perform activities of daily living with little or no assistance~* Adequate bone marrow, liver and kidney~* Understand the nature of this study and give written informed consent.~Exclusion Criteria:~You cannot participate in this study if any of the following apply to you:~* Female patients who are pregnant or are lactating~* History of serious cardiovascular disease within the previous six months~* Serious active infection at the time of treatment~* Other serious underlying medical condition~Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Chemotherapy-naïve patients with unresectable stage III/IV NSCLC received pemetrexed 500 mg/m2 IV and gemcitabine 1500 mg/m2 IV every 2 weeks for 8-12 cycles with restaging every 4 cycles. Patients also received supplemental folate/B12 therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).